Akari Therapeutics PLC
NASDAQ:AKTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Akari Therapeutics PLC
Other Current Liabilities
Akari Therapeutics PLC
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Akari Therapeutics PLC
NASDAQ:AKTX
|
Other Current Liabilities
$485k
|
CAGR 3-Years
-61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-30%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Liabilities
$1.4B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Liabilities
$4.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Liabilities
$25B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Liabilities
$7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Liabilities
$8.5B
|
CAGR 3-Years
30%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
Akari Therapeutics PLC
Glance View
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The company went IPO on 2014-01-31. The firm is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid or leukotriene system and the bioamine system for the treatment of rare and orphan diseases. Its lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4 (LTB4). The company inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement. The company inhibits LTB4 by capturing the fatty acid within the body of the nomacopan protein. The anaphylatoxin (C5a) and the membrane attack complex (MAC) cause and maintain a proinflammatory and prothrombotic state. LTB4 also activates cells via two separate GPCRs and can independently cause and maintain a proinflammatory state.
See Also
What is Akari Therapeutics PLC's Other Current Liabilities?
Other Current Liabilities
485k
USD
Based on the financial report for Dec 31, 2025, Akari Therapeutics PLC's Other Current Liabilities amounts to 485k USD.
What is Akari Therapeutics PLC's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-30%
Over the last year, the Other Current Liabilities growth was -56%. The average annual Other Current Liabilities growth rates for Akari Therapeutics PLC have been -61% over the past three years , and -30% over the past ten years .
